Colin Bristow
Stock Analyst at UBS
(1.63)
# 3,309
Out of 5,182 analysts
105
Total ratings
40.32%
Success rate
-4.98%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Maintains: Neutral | $4 → $10 | $7.20 | +38.89% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $426.01 | +28.17% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $127.75 | -12.33% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $69.22 | +15.57% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.49 | +43.27% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.59 | -37.11% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $28.62 | -40.60% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $340.18 | -6.23% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.52 | +58.73% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.79 | +4.52% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $110.23 | +8.86% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $180.67 | +11.81% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.09 | +1,367.89% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $744.44 | +47.63% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $20.98 | +696.00% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $868.27 | -51.63% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $14.74 | -86.43% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.86 | +867.74% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $197.38 | -26.03% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $57.78 | +29.80% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.83 | +818.73% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.29 | +43.08% | 1 | Aug 23, 2021 |
enGene Therapeutics
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $7.20
Upside: +38.89%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $426.01
Upside: +28.17%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $127.75
Upside: -12.33%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $69.22
Upside: +15.57%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.49
Upside: +43.27%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.59
Upside: -37.11%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $28.62
Upside: -40.60%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $340.18
Upside: -6.23%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.52
Upside: +58.73%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.79
Upside: +4.52%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $110.23
Upside: +8.86%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $180.67
Upside: +11.81%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.09
Upside: +1,367.89%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $744.44
Upside: +47.63%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $20.98
Upside: +696.00%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $868.27
Upside: -51.63%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $14.74
Upside: -86.43%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.86
Upside: +867.74%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $197.38
Upside: -26.03%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $57.78
Upside: +29.80%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.83
Upside: +818.73%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.29
Upside: +43.08%